

Financial Tear Sheet

Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

Stock Information

FCSC (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$2.58
Change (%)	▼ 0.11 (4.09%)
Volume	38,367
52 Week Low	\$1.57
Market Cap	\$37,970,288
Rolling EPS	-1.95
PE Ratio	N/A
Shares Outstanding	14,717,166

Data as of 10/19/17 12:31 p.m. ET



Recent Headlines & Events

10/02/17 - 4:30 p.m.
Fibrocell to Present at 2017 Cell & Gene Meeting on the Mesa

09/26/17 - 8:01 a.m.
Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for

There are currently no events scheduled.

Recessive Dystrophic Epidermolysis Bullosa

09/05/17 - 8:01 a.m.

Fibrocell to Present at Rodman & Renshaw 19th Annual Global Investment Conference and Global Genes' 2017 RARE Patient Advocacy Summit

SEC Filings

Filing Date	Form
10/04/17	8-K
09/26/17	8-K
08/09/17	10-Q
08/09/17	8-K

Corporate Governance

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	39	31.99	54.5	8,020,897
Mutual Fund	15	3.11	7.8	1,154,553
Director and Officer	1	.25	0.7	105,600

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	5,540,140	37.6	0	06/30/17
Fidelity Management & Research Company	850,214	5.8	-18,598	06/30/17
MSD Partners, L.P.	692,960	4.7	0	06/30/17
The Vanguard Group, Inc.	346,576	2.4	-47,690	06/30/17
Renaissance Technologies LLC	108,264	0.7	21,400	06/30/17
Creative Planning, Inc.	61,090	0.4	0	09/30/17
Geode Capital Management, L.L.C.	58,710	0.4	-1,717	06/30/17
Parametric Portfolio Associates LLC	48,259	0.3	35,000	06/30/17
BlackRock Institutional Trust Company, N.A.	41,128	0.3	-25,683	06/30/17
California Public Employees' Retirement System	36,333	0.3	0	06/30/17

Data provided by Nasdaq. Minimum 15 minutes delayed.